Differential susceptibility of white matter tracts to inflammatory mediators in schizophrenia: An integrated DTI study

Schizophrenia Research

Volumn 161, Issue 1, 2015, Pages 119-125

  Prasad, Konasale M ^a   Upton, Catherine H ^a   Nimgaonkar, Vishwajit L ^a   Keshavan, Matcheri S ^b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Connectivity; Cytokines; Immune mediators; Inflammation; Schizophrenia; White matter

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 6; NEUROLEPTIC AGENT;

ADULT; AGE; ARTICLE; CONTROLLED STUDY; DIFFUSION TENSOR IMAGING; FEMALE; FORCEPS MAJOR; FRACTIONAL ANISOTROPY; HUMAN; INFERIOR FRONTOOCCIPITAL FASCICULUS; INFERIOR LONGITUDINAL FASCICULUS; MAJOR CLINICAL STUDY; MALE; NERVOUS SYSTEM INFLAMMATION; PROTEIN BLOOD LEVEL; SCHIZOPHRENIA; SEX; SOCIAL STATUS; WHITE MATTER; ADOLESCENT; ANISOTROPY; COMPLICATION; DISEASE PREDISPOSITION; ENCEPHALITIS; METABOLISM; MYELINATED NERVE; PATHOLOGY; STATISTICS; YOUNG ADULT;

ADOLESCENT; ADULT; ANISOTROPY; C-REACTIVE PROTEIN; DIFFUSION TENSOR IMAGING; DISEASE SUSCEPTIBILITY; ENCEPHALITIS; FEMALE; HUMANS; INTERLEUKIN-6; MALE; NERVE FIBERS, MYELINATED; SCHIZOPHRENIA; STATISTICS AS TOPIC; WHITE MATTER; YOUNG ADULT;

EID: 84920583504     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2014.09.043     Document Type: Article

References (71)

1. Amad A., Cachia A., Gorwood P., Pins D., Delmaire C., Rolland B., Mondino M., Thomas P., Jardri R. The multimodal connectivity of the hippocampal complex in auditory and visual hallucinations. Mol. Psychiatry 2014, 19(2):184-191.
2. Bartzokis G. Age-related myelin breakdown: a developmental model of cognitive decline and Alzheimer's disease. Neurobiol Aging 25(1), 5-18; author reply 49-62.Bartzokis, G., 2004. Age-related myelin breakdown: a developmental model of cognitive decline and Alzheimer's disease. Neurobiol. Aging 2004, 25(1):5-18. (author reply 49-62).
3. Bayer T.A., Buslei R., Havas L., Falkai P. Evidence for activation of microglia in patients with psychiatric illnesses. Neurosci. Lett. 1999, 271(2):126-128.
4. Beaulieu C. The basis of anisotropic water diffusion in the nervous system-a technical review. NMR Biomed. 2002, 15(7-8):435-455.
5. Beaulieu C., Allen P.S. Determinants of anisotropic water diffusion in nerves. Magn. Reson. Med. 1994, 31(4):394-400.
6. Benros M.E., Nielsen P.R., Nordentoft M., Eaton W.W., Dalton S.O., Mortensen P.B. Autoimmune diseases and severe infections as risk factors for schizophrenia: a 30-year population-based register study. Am. J. Psychiatry 2011, 168(12):1303-1310.
7. Black S., Kushner I., Samols D. C-reactive protein. J. Biol. Chem. 2004, 279(47):48487-48490.
8. Burgess P.W., Veitch E., de Lacy Costello A., Shallice T. The cognitive and neuroanatomical correlates of multitasking. Neuropsychologia 2000, 38(6):848-863.
9. Chen S.-J., Chao Y.-L., Chen C.-Y., Chang C.-M., Wu E.C.-H., Wu C.-S., Yeh H.-H., Chen C.-H., Tsai H.-J. Prevalence of autoimmune diseases in in-patients with schizophrenia: nationwide population-based study. Br. J. Psychiatry 2012, 200(5):374-380.
10. Cheung V., Cheung C., McAlonan G.M., Deng Y., Wong J.G., Yip L., Tai K.S., Khong P.L., Sham P., Chua S.E. A diffusion tensor imaging study of structural dysconnectivity in never-medicated, first-episode schizophrenia. Psychol. Med. 2008, 38(6):877-885.
11. Cornblatt B.A., Keilp J.G. Impaired attention, genetics, and the pathophysiology of schizophrenia. Schizophr. Bull. 1994, 20(1):31-46.
12. Curcic-Blake B., Nanetti L., van der Meer L., Cerliani L., Renken R., Pijnenborg G.H., Aleman A. Not on speaking terms: hallucinations and structural network disconnectivity in schizophrenia. Brain Struct. Funct. 2013, (Epub ahead of print 2013 Nov 2).
13. di Penta A., Moreno B., Reix S., Fernandez-Diez B., Villanueva M., Errea O., Escala N., Vandenbroeck K., Comella J.X., Villoslada P. Oxidative stress and proinflammatory cytokines contribute to demyelination and axonal damage in a cerebellar culture model of neuroinflammation. PLoS One 2013, 8(2):e54722.
14. Dickerson F., Stallings C., Origoni A., Boronow J., Yolken R. C-reactive protein is associated with the severity of cognitive impairment but not of psychiatric symptoms in individuals with schizophrenia. Schizophr. Res. 2007, 93(1-3):261-265.
15. Dickerson F., Stallings C., Origoni A., Vaughan C., Khushalani S., Yolken R. Additive effects of elevated C-reactive protein and exposure to Herpes Simplex Virus type 1 on cognitive impairment in individuals with schizophrenia. Schizophr. Res. 2012, 134(1):83-88.
16. Eisenhardt S.U., Thiele J.R., Bannasch H., Stark G.B., Peter K. C-reactive protein: how conformational changes influence inflammatory properties. Cell Cycle 2009, 8(23):3885-3892.
17. Ellison-Wright I., Bullmore E. Meta-analysis of diffusion tensor imaging studies in schizophrenia. Schizophr. Res. 2009, 108(1-3):3-10.
18. Fillman S.G., Cloonan N., Catts V.S., Miller L.C., Wong J., McCrossin T., Cairns M., Weickert C.S. Increased inflammatory markers identified in the dorsolateral prefrontal cortex of individuals with schizophrenia. Mol. Psychiatry 2013, 18(2):206-214.
19. First M.B. The Structured Clinical Interview for DSM-IV for Axis I disorders: Clinical Version, Administration Booklet 1997, American Psychiatric Press, Washington, DC.
20. Fitzsimmons J., Kubicki M., Shenton M.E. Review of functional and anatomical brain connectivity findings in schizophrenia. Curr. Opin. Psychiatry 2013, 26(2):172-187.
21. Friedman J.I., Tang C., Carpenter D., Buchsbaum M., Schmeidler J., Flanagan L., Golembo S., Kanellopoulou I., Ng J., Hof P.R., Harvey P.D., Tsopelas N.D., Stewart D., Davis K.L. Diffusion tensor imaging findings in first-episode and chronic schizophrenia patients. Am. J. Psychiatry 2008, 165(8):1024-1032.
22. Ganguli R., Rabin B.S., Kelly R.H., Lyte M., Ragu U. Clinical and laboratory evidence of autoimmunity in acute schizophrenia. Ann. N. Y. Acad. Sci. 1987, 496:676-685.
23. Gloor P., Salanova V., Olivier A., Quesney L.F. The human dorsal hippocampal commissure. An anatomically identifiable and functional pathway. Brain 1993, 116(Pt 5):1249-1273.
24. Harris L.W., Wayland M., Lan M., Ryan M., Giger T., Lockstone H., Wuethrich I., Mimmack M., Wang L., Kotter M., Craddock R., Bahn S. The cerebral microvasculature in schizophrenia: a laser capture microdissection study. PLoS ONE 2008, 3(12):e3964.
25. Hasan K.M. Diffusion tensor eigenvalues or both mean diffusivity and fractional anisotropy are required in quantitative clinical diffusion tensor MR reports: fractional anisotropy alone is not sufficient. Radiology 2006, 239(2):611-612. (author reply 612-613).
26. Heath R.G., Krupp I.M., Byers L.W., Lijekvist J.I. Schizophrenia as an immunologic disorder. 3. Effects of antimonkey and antihuman brain antibody on brain function. Arch. Gen. Psychiatry 1967, 16(1):24-33.
27. Henneberg A.E., Horter S., Ruffert S. Increased prevalence of antibrain antibodies in the sera from schizophrenic patients. Schizophr. Res. 1994, 14(1):15-22.
28. Hollingshead A.B. Four-Factor Index of Social Status 1975, Yale University, New Haven, CT.
29. Karlsgodt K.H., Niendam T.A., Bearden C.E., Cannon T.D. White matter integrity and prediction of social and role functioning in subjects at ultra-high risk for psychosis. Biol. Psychiatry 2009, 66(6):562-569.
30. Kato A., Watanabe T., Yamazaki M., Deki T., Suzuki M. IL-6R distribution in normal human and cynomolgus monkey tissues. Regul. Toxicol. Pharmacol. RTP 2009, 53(1):46-51.
31. Kelly R.H., Ganguli R., Rabin B.S. Antibody to discrete areas of the brain in normal individuals and patients with schizophrenia. Biol. Psychiatry 1987, 22(12):1488-1491.
32. Kubicki M., Park H., Westin C.F., Nestor P.G., Mulkern R.V., Maier S.E., Niznikiewicz M., Connor E.E., Levitt J.J., Frumin M., Kikinis R., Jolesz F.A., McCarley R.W., Shenton M.E. DTI and MTR abnormalities in schizophrenia: analysis of white matter integrity. NeuroImage 2005, 26(4):1109-1118.
33. Kuta A.E., Baum L.L. C-reactive protein is produced by a small number of normal human peripheral blood lymphocytes. J. Exp. Med. 1986, 164(1):321-326.
34. Lee S.H., Kubicki M., Asami T., Seidman L.J., Goldstein J.M., Mesholam-Gately R.I., McCarley R.W., Shenton M.E. Extensive white matter abnormalities in patients with first-episode schizophrenia: a Diffusion Tensor Imaging (DTI) study. Schizophr. Res. 2013, 143(2-3):231-238.
35. Leibinger M., Muller A., Gobrecht P., Diekmann H., Andreadaki A., Fischer D. Interleukin-6 contributes to CNS axon regeneration upon inflammatory stimulation. Cell Death Dis. 2013, 4:e609.
36. Lisak R.P., Benjamins J.A., Nedelkoska L., Barger J.L., Ragheb S., Fan B., Ouamara N., Johnson T.A., Rajasekharan S., Bar-Or A. Secretory products of multiple sclerosis B cells are cytotoxic to oligodendroglia in vitro. J. Neuroimmunol. 2012, 246(1-2):85-95.
37. Liu X., Lai Y., Wang X., Hao C., Chen L., Zhou Z., Yu X., Hong N. Reduced white matter integrity and cognitive deficit in never-medicated chronic schizophrenia: a diffusion tensor study using TBSS. Behav. Brain Res. 2013, 252:157-163.
38. Liu X., Lai Y., Wang X., Hao C., Chen L., Zhou Z., Yu X., Hong N. A combined DTI and structural MRI study in medicated-naïve chronic schizophrenia. Magn. Reson. Imaging 2014, 32(1):1-8.
39. Marsland A.L., Petersen K.L., Sathanoori R., Muldoon M.F., Neumann S.A., Ryan C., Flory J.D., Manuck S.B. Interleukin-6 covaries inversely with cognitive performance among middle-aged community volunteers. Psychosom. Med. 2006, 68(6):895-903.
40. Marsland A.L., Gianaros P.J., Abramowitch S.M., Manuck S.B., Hariri A.R. Interleukin-6 covaries inversely with hippocampal grey matter volume in middle-aged adults. Biol. Psychiatry 2008, 64(6):484-490.
41. Miller B.J., Culpepper N., Rapaport M.H. C-reactive protein levels in schizophrenia: a review and meta-analysis. Clin. Schizophr. Relat. Psychoses 2014, 7(4):223-230.
42. Mitelman S.A., Torosjan Y., Newmark R.E., Schneiderman J.S., Chu K.-W., Brickman A.M., Haznedar M.M., Hazlett E.A., Tang C.Y., Shihabuddin L., Buchsbaum M.S. Internal capsule, corpus callosum and long associative fibers in good and poor outcome schizophrenia: a diffusion tensor imaging survey. Schizophr. Res. 2007, 92(1-3):211-224.
43. Muller N., Schwarz M.J. Immune system and schizophrenia. Curr. Immunol. Rev. 2010, 6(3):213-220.
44. Muller N., Riedel M., Scheppach C., Brandstatter B., Sokullu S., Krampe K., Ulmschneider M., Engel R.R., Moller H.J., Schwarz M.J. Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. Am. J. Psychiatry 2002, 159(6):1029-1034.
45. Muller N., Krause D., Dehning S., Musil R., Schennach-Wolff R., Obermeier M., Moller H.J., Klauss V., Schwarz M.J., Riedel M. Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment. Schizophr. Res. 2010, 121(1-3):118-124.
46. Neville H.J. Flexibility and Plasticity in Cortical Development 2006, 287-314. Oxford University Press, Oxford. Y. Munakata, M.H. Johnson (Eds.).
47. Ortibus E., Verhoeven J., Sunaert S., Casteels I., de Cock P., Lagae L. Integrity of the inferior longitudinal fasciculus and impaired object recognition in children: a diffusion tensor imaging study. Dev. Med. Child Neurol. 2012, 54(1):38-43.
48. Perez-Iglesias R., Tordesillas-Gutierrez D., Barker G.J., McGuire P.K., Roiz-Santianez R., Mata I., de Lucas E.M., Quintana F., Vazquez-Barquero J.L., Crespo-Facorro B. White matter defects in first episode psychosis patients: a voxelwise analysis of diffusion tensor imaging. NeuroImage 2010, 49(1):199-204.
49. Perez-Iglesias R., Tordesillas-Gutierrez D., McGuire P.K., Barker G.J., Roiz-Santianez R., Mata I., de Lucas E.M., Rodriguez-Sanchez J.M., Ayesa-Arriola R., Vazquez-Barquero J.L., Crespo-Facorro B. White matter integrity and cognitive impairment in first-episode psychosis. Am. J. Psychiatry 2010, 167(4):451-458.
50. Philippi C.L., Mehta S., Grabowski T., Adolphs R., Rudrauf D. Damage to association fiber tracts impairs recognition of the facial expression of emotion. J. Neurosci. 2009, 29(48):15089-15099.
51. Potvin S., Stip E., Sepehry A.A., Gendron A., Bah R., Kouassi E. Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol. Psychiatry 2008, 63(8):801-808.
52. Power J., Mayer-Proschel M., Smith J., Noble M. Oligodendrocyte precursor cells from different brain regions express divergent properties consistent with the differing time courses of myelination in these regions. Dev. Biol. 2002, 245(2):362-375.
53. Purcell S.M., Wray N.R., Stone J.L., Visscher P.M., O'Donovan M.C., Sullivan P.F., Sklar P. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 2009, 460(7256):748-752.
54. Radewicz K., Garey L.J., Gentleman S.M., Reynolds R. Increase in HLA-DR immunoreactive microglia in frontal and temporal cortex of chronic schizophrenics. J. Neuropathol. Exp. Neurol. 2000, 59(2):137-150.
55. Ripke S., Sanders A.R., Kendler K.S., Levinson D.F., Sklar P., Holmans P.A., Lin D.Y., Duan J., Ophoff R.A., Andreassen O.A., Scolnick E., Cichon S., St Clair D., Corvin A., Gurling H., Werge T., Rujescu D., Blackwood D.H., Pato C.N., Malhotra A.K., Purcell S., Dudbridge F., Neale B.M., Rossin L., Visscher P.M., Posthuma D., Ruderfer D.M., Fanous A., Stefansson H., Steinberg S., Mowry B.J., Golimbet V., De Hert M., Jonsson E.G., Bitter I., Pietilainen O.P., Collier D.A., Tosato S., Agartz I., Albus M., Alexander M., Amdur R.L., Amin F., Bass N., Bergen S.E., Black D.W., Borglum A.D., Brown M.A., Bruggeman R., Buccola N.G., Byerley W.F., Cahn W., Cantor R.M., Carr V.J., Catts S.V., Choudhury K., Cloninger C.R., Cormican P., Craddock N., Danoy P.A., Datta S., de Haan L., Demontis D., Dikeos D., Djurovic S., Donnelly P., Donohoe G., Duong L., Dwyer S., Fink-Jensen A., Freedman R., Freimer N.B., Friedl M., Georgieva L., Giegling I., Gill M., Glenthoj B., Godard S., Hamshere M., Hansen M., Hansen T., Hartmann A.M., Henskens F.A., Hougaard D.M., Hultman C.M., Ingason A., Jablensky A.V., Jakobsen K.D., Jay M., Jurgens G., Kahn R.S., Keller M.C., Kenis G., Kenny E., Kim Y., Kirov G.K., Konnerth H., Konte B., Krabbendam L., Krasucki R., Lasseter V.K., Laurent C., Lawrence J., Lencz T., Lerer F.B., Liang K.Y., Lichtenstein P., Lieberman J.A., Linszen D.H., Lonnqvist J., Loughland C.M., Maclean A.W., Maher B.S., Maier W., Mallet J., Malloy P., Mattheisen M., Mattingsdal M., McGhee K.A., McGrath J.J., McIntosh A., McLean D.E., McQuillin A., Melle I., Michie P.T., Milanova V., Morris D.W., Mors O., Mortensen P.B., Moskvina V., Muglia P., Myin-Germeys I., Nertney D.A., Nestadt G., Nielsen J., Nikolov I., Nordentoft M., Norton N., Nothen M.M., O'Dushlaine C.T., Olincy A., Olsen L., O'Neill F.A., Orntoft T.F., Owen M.J., Pantelis C., Papadimitriou G., Pato M.T., Peltonen L., Petursson H., Pickard B., Pimm J., Pulver A.E., Puri V., Quested D., Quinn E.M., Rasmussen H.B., Rethelyi J.M., Ribble R., Rietschel M., Riley B.P., Ruggeri M., Schall U., Schulze T.G., Schwab S.G., Scott R.J., Shi J., Sigurdsson E., Silverman J.M., Spencer C.C., Stefansson K., Strange A., Strengman E., Stroup T.S., Suvisaari J., Terenius L., Thirumalai S., Thygesen J.H., Timm S., Toncheva D., van den Oord E., van Os J., van Winkel R., Veldink J., Walsh D., Wang A.G., Wiersma D., Wildenauer D.B., Williams H.J., Williams N.M., Wormley B., Zammit S., Sullivan P.F., O'Donovan M.C., Daly M.J., Gejman P.V. Genome-wide association study identifies five new schizophrenia loci. Nat. Genet. 2011, 43(10):969-976.
56. Rossi F., Giorgio A., Battaglini M., Stromillo M.L., Portaccio E., Goretti B., Federico A., Hakiki B., Amato M.P., De Stefano N. Relevance of brain lesion location to cognition in relapsing multiple sclerosis. PLoS One 2012, 7(11):e44826.
57. Rothermundt M., Arolt V., Bayer T.A. Review of immunological and immunopathological findings in schizophrenia. Brain Behav. Immun. 2001, 15(4):319-339.
58. Saetre P., Emilsson L., Axelsson E., Kreuger J., Lindholm E., Jazin E. Inflammation-related genes up-regulated in schizophrenia brains. BMC Psychiatry 2007, 7:46.
59. Sharma T. Cogtest: Computerized Neurocognitive Test Battery for Clinical Trials 2003.
60. Shi J., Levinson D.F., Duan J., Sanders A.R., Zheng Y., Pe'er I., Dudbridge F., Holmans P.A., Whittemore A.S., Mowry B.J., Olincy A., Amin F., Cloninger C.R., Silverman J.M., Buccola N.G., Byerley W.F., Black D.W., Crowe R.R., Oksenberg J.R., Mirel D.B., Kendler K.S., Freedman R., Gejman P.V. Common variants on chromosome 6p22.1 are associated with schizophrenia. Nature 2009, 460(7256):753-757.
61. Smith S.M., Jenkinson M., Johansen-Berg H., Rueckert D., Nichols T.E., Mackay C.E., Watkins K.E., Ciccarelli O., Cader M.Z., Matthews P.M., Behrens T.E. Tract-based spatial statistics: voxelwise analysis of multi-subject diffusion data. NeuroImage 2006, 31(4):1487-1505.
62. Sommer I.E., de Witte L., Begemann M., Kahn R.S. Nonsteroidal anti-inflammatory drugs in schizophrenia: ready for practice or a good start? A meta-analysis. J. Clin. Psychiatry 2012, 73(4):414-419.
63. Stefansson H., Ophoff R.A., Steinberg S., Andreassen O.A., Cichon S., Rujescu D., Werge T., Pietilainen O.P., Mors O., Mortensen P.B., Sigurdsson E., Gustafsson O., Nyegaard M., Tuulio-Henriksson A., Ingason A., Hansen T., Suvisaari J., Lonnqvist J., Paunio T., Borglum A.D., Hartmann A., Fink-Jensen A., Nordentoft M., Hougaard D., Norgaard-Pedersen B., Bottcher Y., Olesen J., Breuer R., Moller H.J., Giegling I., Rasmussen H.B., Timm S., Mattheisen M., Bitter I., Rethelyi J.M., Magnusdottir B.B., Sigmundsson T., Olason P., Masson G., Gulcher J.R., Haraldsson M., Fossdal R., Thorgeirsson T.E., Thorsteinsdottir U., Ruggeri M., Tosato S., Franke B., Strengman E., Kiemeney L.A., Melle I., Djurovic S., Abramova L., Kaleda V., Sanjuan J., de Frutos R., Bramon E., Vassos E., Fraser G., Ettinger U., Picchioni M., Walker N., Toulopoulou T., Need A.C., Ge D., Yoon J.L., Shianna K.V., Freimer N.B., Cantor R.M., Murray R., Kong A., Golimbet V., Carracedo A., Arango C., Costas J., Jonsson E.G., Terenius L., Agartz I., Petursson H., Nothen M.M., Rietschel M., Matthews P.M., Muglia P., Peltonen L., St Clair D., Goldstein D.B., Stefansson K., Collier D.A. Common variants conferring risk of schizophrenia. Nature 2009, 460(7256):744-747.
64. Stolz E., Pancholi K.M., Goradia D.D., Paul S., Keshavan M.S., Nimgaonkar V.L., Prasad K.M. Brain activation patterns during visual episodic memory processing among first-degree relatives of schizophrenia subjects. NeuroImage 2012, 63(3):1154-1161.
65. Tang Y., Nyengaard J.R., Pakkenberg B., Gundersen H.J. Age-induced white matter changes in the human brain: a stereological investigation. Neurobiol. Aging 1997, 18(6):609-615.
66. Tsutsui K., Kanbayashi T., Tanaka K., Boku S., Ito W., Tokunaga J., Mori A., Hishikawa Y., Shimizu T., Nishino S. Anti-NMDA-receptor antibody detected in encephalitis, schizophrenia, and narcolepsy with psychotic features. BMC Psychiatry 2012, 12(1):37.
67. Tusa R.J., Ungerleider L.G. The inferior longitudinal fasciculus: a reexamination in humans and monkeys. Ann. Neurol. 1985, 18(5):583-591.
68. Valerio A., Ferrario M., Dreano M., Garotta G., Spano P., Pizzi M. Soluble interleukin-6 (IL-6) receptor/IL-6 fusion protein enhances in vitro differentiation of purified rat oligodendroglial lineage cells. Mol. Cell. Neurosci. 2002, 21(4):602-615.
69. Weaver J.D., Huang M.H., Albert M., Harris T., Rowe J.W., Seeman T.E. Interleukin-6 and risk of cognitive decline: MacArthur studies of successful aging. Neurology 2002, 59(3):371-378.
70. Wierzba-Bobrowicz T., Lewandowska E., Lechowicz W., Stepien T., Pasennik E. Quantitative analysis of activated microglia, ramified and damage of processes in the frontal and temporal lobes of chronic schizophrenics. Folia Neuropathol. Assoc. Pol. Neuropathol. Med. Res. Cent. Pol. Acad. Sci. 2005, 43(2):81-89.
71. Yasojima K., Schwab C., McGeer E.G., McGeer P.L. Human neurons generate C-reactive protein and amyloid P: upregulation in Alzheimer's disease. Brain Res. 2000, 887(1):80-89.